Previous Page
14
nanotimes
Companies Facts
B Index®
ioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) has been added to the NASDAQ Biotechnology (Symbol: NBI), effective prior to the stock
market open on November 21, 2011.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classifi- cation Benchmark (ICB). The NASDAQ Biotechnolo- gy Index is a modified market capitalization-weighted index, and the index securities are evaluated semi- annually in May and November.
Moreover, BioSante Pharmaceuticals announced the issuance of a new U.S. patent covering the “method of use” of LibiGel (testosterone gel) for treating fe- male sexual dysfunction (FSD) and hypoactive sexual desire disorder (HSDD). The patent covers methods for treating FSD and HSDD and also includes using a metered dosage device to deliver the defined dose of the testosterone formulation in LibiGel. U.S. Patent No. 8,067,399, which issued now, will expire on December 29, 2028. The two named inventors of this new patent are a current and a former employee of BioSante.
http://www.biosantepharma.com B
ruker announced the launch of the advanced, G4 ICARUS version C-HF, a new competitively-
priced metals combustion gas analyzer designed for rapid and precise carbon measurements in metal casting and heat treatment applications. Carburiza- tion shim stocks, cast iron and other carbon applica- tions now become easy with the G4 ICARUS C-HF.
C
abot Microelectronics Corporation (NASDAQ: CCMP) intends to pay a special cash dividend
of $15 per share, or approximately $345 million in aggregate, to its shareholders during the first quarter of calendar year 2012. Approximately half of the di- vidend is expected to be funded from the company’s cash balance, and the remaining amount is expected to be funded with new debt. Payment of the special dividend is contingent upon arranging the associ- ated financing with terms and conditions that are acceptable to the company. In addition, the Board has authorized an increase in the company’s existing share repurchase program to $150 million, from the previous available authorization of approximately $83 million. The company intends to continue to repurchase its shares from time to time in open mar- ket transactions, depending on market conditions, at management’s discretion.
11-11/12 :: November/December 2011
© Bruker